Received Aug 26, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | DL4YY | — |
underage administration; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 19-month-old male patient who received Men ACWY-CRM NVS (Menveo) (batch number DL4YY, expiry date 30-APR-2026) for prophylaxis. Concurrent medical conditions included sickle-cell anemia. On 21-AUG-2025, the patient received Menveo. On 21-AUG-2025, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: underage administration). The outcome of the inappropriate age at vaccine administration was not applicable. Additional Information: GSK Receipt Date: 21-AUG-2025 The nurse reported that a patient suffers sickle cell anemia received the Menveo one vial vaccine (nineteen-month-old patient), which led to inappropriate age at vaccine administration. Since the patient was not administered with the two vial Menveo, wanted to know there was any concern/advise on this situation. The vaccination date, vaccine detail and patient demographics were obtained in this call. No further information was obtained in this call. The vaccine administration facility was the same as primary reporter.
Sickle-cell anemia